Molecular Templates - MTEM Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Molecular Templates in the last year. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MTEM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MTEM, but not buy additional shares or sell existing shares.
View MTEM analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued 12-month price objectives for Molecular Templates' stock. Their MTEM share price forecasts range from $1.00 to $9.00. On average, they predict the company's share price to reach $3.83 in the next year. This suggests a possible upside of 707.7% from the stock's current price.
View analysts price targets for MTEM or view top-rated stocks among Wall Street analysts.

Molecular Templates' stock was trading at $3.92 at the start of the year. Since then, MTEM shares have decreased by 87.9% and is now trading at $0.4746.
View the best growth stocks for 2022 here.

Molecular Templates saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 429,100 shares, a drop of 19.6% from the October 31st total of 533,500 shares. Based on an average daily volume of 105,500 shares, the days-to-cover ratio is currently 4.1 days. Currently, 1.0% of the shares of the company are sold short.
View Molecular Templates' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our MTEM earnings forecast.

Molecular Templates, Inc. (NASDAQ:MTEM) released its quarterly earnings data on Thursday, November, 10th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.48) by $0.04. The biotechnology company earned $4.24 million during the quarter, compared to the consensus estimate of $4 million. Molecular Templates had a negative trailing twelve-month return on equity of 226.71% and a negative net margin of 231.40%.

Shares of Molecular Templates reverse split before market open on Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, August 1st 2017. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Novavax (NVAX), Gilead Sciences (GILD), TG Therapeutics (TGTX), CEL-SCI (CVM), Pfizer (PFE), Synergy Pharmaceuticals (SGYP), Amarin (AMRN), Corbus Pharmaceuticals (CRBP) and Exelixis (EXEL).

Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."

Molecular Templates' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.11%), Renaissance Technologies LLC (1.03%), Kingsbury Capital Investment Advisors LLC (0.53%), Two Sigma Advisers LP (0.45%) and Two Sigma Investments LP (0.39%). Insiders that own company stock include Jason S Kim, Kevin M Lalande, Longitude Capital Partners Iii, Sean Mclennan, Shv Management Services, Llc and Target N V Biotech.
View institutional ownership trends.

Shares of MTEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MTEM stock can currently be purchased for approximately $0.47.

Molecular Templates (NASDAQ:MTEM) has a market capitalization of $26.74 million and generates $38.70 million in revenue each year. The biotechnology company earns $-83,010,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis.

The company employs 261 workers across the globe.

Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The official website for the company is www.mtem.com. The biotechnology company can be reached via phone at (512) 869-1555, via email at adam.cutler@mtem.com, or via fax at 650-474-2529.